Relenza Studies In High-Risk Populations Might Show More Efficacy - Cmte.

Additional studies of Glaxo Wellcome's Relenza Diskhaler should be targeted to specific high-risk populations in order to more clearly show efficacy of zanamivir against influenza, members of FDA's Antiviral Drugs Advisory Committee said Feb. 24.